Blockchain Registration Transaction Record

Telomir Pharma Raises $5.6M for TNBC Trial

Telomir Pharmaceuticals (NASDAQ: TELO) secures $5.6M PIPE financing to advance Telomir-Zn into Phase 1/2 trials for triple-negative breast cancer. FDA IND cleared.

This financing provides Telomir Pharmaceuticals with critical capital to advance Telomir-Zn into first-in-human trials for triple-negative breast cancer, a particularly aggressive and hard-to-treat disease with limited therapeutic options. The FDA's IND clearance and the backing from existing investors, including John Paul DeJoria, underscore confidence in the company's novel approach targeting epigenetic and metabolic pathways. If successful, Telomir-Zn could offer a new treatment paradigm for TNBC patients and potentially other cancers, making this a significant development in oncology. For investors, the non-dilutive structure of the PIPE (no warrants) may be seen as a positive signal, though clinical-stage biotech remains high-risk.